Insiders Are Scooping Up These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
Zenas BioPharma's Key Milestones And Market Context: Holding Through The BLA [Seeking Alpha]
Zenas BioPharma (ZBIO) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Zenas BioPharma Funding Shifts Focus From Survival Risk To Execution Risk [Yahoo! Finance]
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million